Latest News
Enliven Therapeutics, Inc.
- Enliven Therapeutics CMO Collins sells $192,342 in ELVN stock By Investing.com
- Enliven Therapeutics CFO Hohl sells $231,545 in shares By Investing.com
- Enliven Therapeutics CMO Collins sells $192,342 in ELVN stock By Investing.com
- Form 4 Enliven Therapeutics Inc: Helen Louise Collins (CHIEF MEDICAL OFFICER) For: 19 October
- Enliven Therapeutics Appoints Kristine Ball To Board Of Directors Ahead Of Planned Phase 3 Trial Initiation This Year
- Enliven Therapeutics appoints Kristine Ball to Board and Audit Committee
- Enliven Therapeutics, Inc. (ELVN) Adds Kristine Ball to Board
- Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
- FDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinib
- Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
- Enliven Therapeutics Director Sold Shares Worth Over $606K
- Morgan Stanley initiates Enliven Therapeutics stock at overweight
Headlines from the last 30 days, linking to the original publishers. See all market news →